Hindustan Bio Sciences（532041）株式概要ヒンドゥスタン・バイオサイエンシズ社は、インドで製薬・バイオテクノロジー部門を運営している。 詳細532041 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6リスク分析収益が 100 万ドル未満 ( ₹4M )意味のある時価総額がありません ( ₹70M )すべてのリスクチェックを見る532041 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW469,747 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA469,747 investors already sharing narrativesYour Fair Value₹Current Price₹6.82211.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-22m36m2016201920222025202620282031Revenue ₹6.2mEarnings ₹1.1mAdvancedSet Fair ValueView all narrativesHindustan Bio Sciences Limited 競合他社Nirman Agri GeneticsSymbol: NSEI:NIRMANMarket cap: ₹243.9mZenotech LaboratoriesSymbol: BSE:532039Market cap: ₹2.8bBeryl DrugsSymbol: BSE:524606Market cap: ₹114.1mDecipher LabsSymbol: BSE:524752Market cap: ₹57.6m価格と性能株価の高値、安値、推移の概要Hindustan Bio Sciences過去の株価現在の株価₹6.8252週高値₹9.9252週安値₹5.00ベータ-0.661ヶ月の変化-5.28%3ヶ月変化-19.58%1年変化-16.83%3年間の変化16.38%5年間の変化79.47%IPOからの変化3,310.00%最新ニュースお知らせ • Aug 03Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026, at 10:00 Indian Standard Time.Reported Earnings • Aug 02First quarter 2027 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 1Q 2026)First quarter 2027 results: ₹0.11 loss per share (down from ₹0.01 profit in 1Q 2026). Net loss: ₹1.13m (down ₹1.27m from profit in 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2027 Results on Jul 31, 2026Hindustan Bio Sciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.お知らせ • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026最新情報をもっと見るRecent updatesお知らせ • Aug 03Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026, at 10:00 Indian Standard Time.Reported Earnings • Aug 02First quarter 2027 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 1Q 2026)First quarter 2027 results: ₹0.11 loss per share (down from ₹0.01 profit in 1Q 2026). Net loss: ₹1.13m (down ₹1.27m from profit in 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2027 Results on Jul 31, 2026Hindustan Bio Sciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.お知らせ • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026お知らせ • Oct 16Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025お知らせ • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad IndiaNew Risk • Aug 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin).Reported Earnings • Aug 01First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.08 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.08 in 1Q 2025). Revenue: ₹3.35m (down 21% from 1Q 2025). Net income: ₹140.0k (down 83% from 1Q 2025). Profit margin: 4.2% (down from 19% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 21Hindustan Bio Sciences Limited to Report Q1, 2026 Results on Jul 31, 2025Hindustan Bio Sciences Limited announced that they will report Q1, 2026 results on Jul 31, 2025New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹8.1m revenue, or US$94k). Market cap is less than US$10m (₹89.0m market cap, or US$1.03m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.10 (vs ₹0.056 in FY 2024)Full year 2025 results: EPS: ₹0.10 (up from ₹0.056 in FY 2024). Revenue: ₹8.13m (down 23% from FY 2024). Net income: ₹1.01m (up 75% from FY 2024). Profit margin: 12% (up from 5.5% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2025 Results on May 30, 2025Hindustan Bio Sciences Limited announced that they will report Q4, 2025 results on May 30, 2025お知らせ • Apr 23Hindustan Bio Sciences Limited Appoints Devanshu Ravinder Dange as Company Secretary and Compliance Officer, Effective April 23, 2025Hindustan Bio Sciences Limited announced that at the board meeting held on April 23, 2025 the board approved appointment of Mr. Devanshu Ravinder Dange as Company Secretary and Compliance Officer. Reason for Change: Appointed on account of resignation of the previous Company Secretary. Date of appointment is April 23, 2025. Brief Profile: Mr. Devanshu Ravinder Dange is an Associate Member of the Institute of Company Secretaries of India(ICSI). He holds Bachelor's Degree in Commerce from Osmania University. In addition, he is certified in Series XI - Merchant Banking from the National Institute of Securities Markets (NISM).Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹8.32, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 77% over the past three years.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹7.27, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 46x in the Biotechs industry in India. Total returns to shareholders of 53% over the past three years.お知らせ • Jan 20Hindustan Bio Sciences Limited to Report Q3, 2025 Results on Jan 30, 2025Hindustan Bio Sciences Limited announced that they will report Q3, 2025 results on Jan 30, 2025New Risk • Jan 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (₹12m revenue, or US$134k). Market cap is less than US$10m (₹104.7m market cap, or US$1.22m).お知らせ • Dec 31Hindustan Bio Sciences Limited Announces Resignation of Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that resignation of Mrs. Sukavasi Jyotsna (ACS 68536) for the post of Company Secretary and Compliance Officer has been approved. Date of Resignation: 31 December 2024.Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹11.50, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 171% over the past three years.お知らせ • Oct 17Hindustan Bio Sciences Limited to Report Q2, 2025 Results on Oct 30, 2024Hindustan Bio Sciences Limited announced that they will report Q2, 2025 results on Oct 30, 2024Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹9.61, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 33x in the Biotechs industry in India. Total returns to shareholders of 163% over the past three years.New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹15m revenue, or US$177k). Market cap is less than US$10m (₹94.2m market cap, or US$1.13m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 155% over the past three years.お知らせ • Jul 31Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time. Location: plot no,31, sagar, society, road no.2, banjarahills, hyderabad-500034, hyderabad Indiaお知らせ • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2025 Results on Jul 31, 2024Hindustan Bio Sciences Limited announced that they will report Q1, 2025 results on Jul 31, 2024お知らせ • May 12Hindustan Bio Sciences Limited to Report Fiscal Year 2024 Results on May 25, 2024Hindustan Bio Sciences Limited announced that they will report fiscal year 2024 results on May 25, 2024お知らせ • Jan 12Hindustan Bio Sciences Limited to Report Q3, 2024 Results on Jan 31, 2024Hindustan Bio Sciences Limited announced that they will report Q3, 2024 results on Jan 31, 2024お知らせ • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2024 Results on Oct 31, 2023Hindustan Bio Sciences Limited announced that they will report Q2, 2024 results on Oct 31, 2023お知らせ • Sep 05Hindustan Bio Sciences Limited Announces Resignation of Goli Seshavataram, Chief Financial OfficerHindustan Bio Sciences Limited announced that Mr. Goli Seshavataram CFO, of the Company has tendered his resignation from the post of the CFO of the Company with effect from August 30, 2023.お知らせ • Aug 19Hindustan Bio Sciences Limited Appoints Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that appointment of Mrs. Sukavasi Jyotsna for the post of Company Secretary and Compliance Officer has been approved. Date of Appointment 18th August, 2023. Mrs. Sukavasi Jyotsna is an Associate Member of the Institute of Company Secretaries of India having membership No. ACS 68536. She holds Bachelor Degree in Commerce and having 1 years of experience in the field of Company Secretarial works.お知らせ • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Agenda: To approve the re-appointment of Mr. Venkata Rama Mohan Raju Jampana.お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2023 Results on May 30, 2023Hindustan Bio Sciences Limited announced that they will report Q4, 2023 results on May 30, 2023Board Change • May 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Non Executive Independent Director Mantena Raju was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.05 (vs ₹0.002 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.05 (up from ₹0.002 loss in 3Q 2022). Revenue: ₹3.18m (up 33% from 3Q 2022). Net income: ₹476.0k (up ₹496.0k from 3Q 2022). Profit margin: 15% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.お知らせ • Jan 23Hindustan Bio Sciences Limited to Report Q3, 2023 Results on Jan 31, 2023Hindustan Bio Sciences Limited announced that they will report Q3, 2023 results on Jan 31, 2023お知らせ • Jan 13Hindustan Bio Sciences Limited Announces Resignation of Varun Varma Jampana as Non Executive-Non Independent DirectorHindustan Bio Sciences Limited announced that Mr. Varun Varma Jampana, Non Executive-Non Independent Director of the company, vide his letter dated 12 January 2023 has tendered his resignation as Non Executive-Non Independent Director of the company with effect from 12 January 2023.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03Second quarter 2023 earnings released: ₹0.07 loss per share (vs ₹0.05 loss in 2Q 2022)Second quarter 2023 results: ₹0.07 loss per share (further deteriorated from ₹0.05 loss in 2Q 2022). Net loss: ₹749.0k (loss widened 36% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.お知らせ • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2023 Results on Oct 31, 2022Hindustan Bio Sciences Limited announced that they will report Q2, 2023 results on Oct 31, 2022お知らせ • Jul 30Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022.お知らせ • Jul 19Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 29, 2022Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results at 2:00 PM, Indian Standard Time on Jul 29, 2022Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 08Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹0.002 loss per share (up from ₹0.11 loss in 3Q 2021). Revenue: ₹2.40m (up ₹2.39m from 3Q 2021). Net loss: ₹20.0k (loss narrowed 98% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings.Reported Earnings • Nov 03Second quarter 2022 earnings released: ₹0.05 loss per share (vs ₹0.03 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹524.0k (down 84% from 2Q 2021). Net loss: ₹550.0k (down 286% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 09First quarter 2022 earnings released: ₹0.07 loss per share (vs ₹0.05 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹1.94m (down 65% from 1Q 2021). Net loss: ₹754.0k (down 250% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 01Third quarter 2021 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹2.0k (down 100% from 3Q 2020). Net loss: ₹1.13m (down ₹1.28m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 76% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Dec 07New 90-day high: ₹3.33The company is up 16% from its price of ₹2.88 on 08 September 2020. The Indian market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 17% share price gain to ₹2.17, the stock is trading at a trailing P/E ratio of 13.4x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 61x in the Biotechs industry in Asia. Total returns to shareholders over the past three years are 309%.Is New 90 Day High Low • Nov 11New 90-day low: ₹1.73The company is down 6.0% from its price of ₹1.84 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.お知らせ • Jul 18Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 31, 2020Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results on Jul 31, 2020株主還元532041IN BiotechsIN 市場7D0.1%-0.3%-0.2%1Y-16.8%14.7%2.4%株主還元を見る業界別リターン: 532041過去 1 年間で14.7 % の収益を上げたIndian Biotechs業界を下回りました。リターン対市場: 532041は、過去 1 年間で2.4 % のリターンを上げたIndian市場を下回りました。価格変動Is 532041's price volatile compared to industry and market?532041 volatility532041 Average Weekly Movement6.2%Biotechs Industry Average Movement8.3%Market Average Movement5.9%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.6%安定した株価: 532041 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 532041の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19912Jampana Venkata Rama Rajuwww.hindustanbiosciences.inヒンドゥスタン・バイオ・サイエンシズ社はインドの製薬・バイオテクノロジー分野で事業を展開。遺伝子組換えヒトエリスロポエチン製剤を提供。また、錠剤、カプセル剤、ドロップ剤、外用剤、シロップ剤など様々な形態の製品を提供している。また、医薬品貿易も行っている。製品の輸出も行っている。同社は1991年に設立され、インドのハイデラバードに拠点を置く。もっと見るHindustan Bio Sciences Limited 基礎のまとめHindustan Bio Sciences の収益と売上を時価総額と比較するとどうか。532041 基礎統計学時価総額₹69.91m収益（TTM）-₹2.06m売上高(TTM)₹4.02m17.4xP/Sレシオ-34.0xPER（株価収益率532041 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計532041 損益計算書（TTM）収益₹4.02m売上原価₹2.37m売上総利益₹1.65mその他の費用₹3.71m収益-₹2.06m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.20グロス・マージン41.03%純利益率-51.18%有利子負債／自己資本比率284.4%532041 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 20:03終値2026/08/24 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hindustan Bio Sciences Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 03Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026, at 10:00 Indian Standard Time.
Reported Earnings • Aug 02First quarter 2027 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 1Q 2026)First quarter 2027 results: ₹0.11 loss per share (down from ₹0.01 profit in 1Q 2026). Net loss: ₹1.13m (down ₹1.27m from profit in 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2027 Results on Jul 31, 2026Hindustan Bio Sciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026
お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.
お知らせ • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026
お知らせ • Aug 03Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2026, at 10:00 Indian Standard Time.
Reported Earnings • Aug 02First quarter 2027 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 1Q 2026)First quarter 2027 results: ₹0.11 loss per share (down from ₹0.01 profit in 1Q 2026). Net loss: ₹1.13m (down ₹1.27m from profit in 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2027 Results on Jul 31, 2026Hindustan Bio Sciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026
お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2026 Results on May 30, 2026Hindustan Bio Sciences Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹8.18, the stock trades at a trailing P/E ratio of 56.7x. Average trailing P/E is 57x in the Biotechs industry in India. Total returns to shareholders of 107% over the past three years.
お知らせ • Jan 19Hindustan Bio Sciences Limited to Report Q3, 2026 Results on Jan 31, 2026Hindustan Bio Sciences Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Jan 31, 2026
お知らせ • Oct 16Hindustan Bio Sciences Limited to Report Q2, 2026 Results on Oct 31, 2025Hindustan Bio Sciences Limited announced that they will report Q2, 2026 results on Oct 31, 2025
お知らせ • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2025, at 10:00 Indian Standard Time. Location: #31, sagar society, road no. 2, banjara hills, hyderabad - 500 034, hyderabad India
New Risk • Aug 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.6% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹7.2m revenue, or US$83k). Market cap is less than US$10m (₹94.3m market cap, or US$1.08m). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (4.6% net profit margin).
Reported Earnings • Aug 01First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.08 in 1Q 2025)First quarter 2026 results: EPS: ₹0.01 (down from ₹0.08 in 1Q 2025). Revenue: ₹3.35m (down 21% from 1Q 2025). Net income: ₹140.0k (down 83% from 1Q 2025). Profit margin: 4.2% (down from 19% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 21Hindustan Bio Sciences Limited to Report Q1, 2026 Results on Jul 31, 2025Hindustan Bio Sciences Limited announced that they will report Q1, 2026 results on Jul 31, 2025
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.1% operating cash flow to total debt). Revenue is less than US$1m (₹8.1m revenue, or US$94k). Market cap is less than US$10m (₹89.0m market cap, or US$1.03m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).
Reported Earnings • Jun 02Full year 2025 earnings released: EPS: ₹0.10 (vs ₹0.056 in FY 2024)Full year 2025 results: EPS: ₹0.10 (up from ₹0.056 in FY 2024). Revenue: ₹8.13m (down 23% from FY 2024). Net income: ₹1.01m (up 75% from FY 2024). Profit margin: 12% (up from 5.5% in FY 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2025 Results on May 30, 2025Hindustan Bio Sciences Limited announced that they will report Q4, 2025 results on May 30, 2025
お知らせ • Apr 23Hindustan Bio Sciences Limited Appoints Devanshu Ravinder Dange as Company Secretary and Compliance Officer, Effective April 23, 2025Hindustan Bio Sciences Limited announced that at the board meeting held on April 23, 2025 the board approved appointment of Mr. Devanshu Ravinder Dange as Company Secretary and Compliance Officer. Reason for Change: Appointed on account of resignation of the previous Company Secretary. Date of appointment is April 23, 2025. Brief Profile: Mr. Devanshu Ravinder Dange is an Associate Member of the Institute of Company Secretaries of India(ICSI). He holds Bachelor's Degree in Commerce from Osmania University. In addition, he is certified in Series XI - Merchant Banking from the National Institute of Securities Markets (NISM).
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹8.32, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 49x in the Biotechs industry in India. Total returns to shareholders of 77% over the past three years.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹7.27, the stock trades at a trailing P/E ratio of 51.3x. Average trailing P/E is 46x in the Biotechs industry in India. Total returns to shareholders of 53% over the past three years.
お知らせ • Jan 20Hindustan Bio Sciences Limited to Report Q3, 2025 Results on Jan 30, 2025Hindustan Bio Sciences Limited announced that they will report Q3, 2025 results on Jan 30, 2025
New Risk • Jan 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (27% accrual ratio). Revenue is less than US$1m (₹12m revenue, or US$134k). Market cap is less than US$10m (₹104.7m market cap, or US$1.22m).
お知らせ • Dec 31Hindustan Bio Sciences Limited Announces Resignation of Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that resignation of Mrs. Sukavasi Jyotsna (ACS 68536) for the post of Company Secretary and Compliance Officer has been approved. Date of Resignation: 31 December 2024.
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹11.50, the stock trades at a trailing P/E ratio of 45x. Average trailing P/E is 44x in the Biotechs industry in India. Total returns to shareholders of 171% over the past three years.
お知らせ • Oct 17Hindustan Bio Sciences Limited to Report Q2, 2025 Results on Oct 30, 2024Hindustan Bio Sciences Limited announced that they will report Q2, 2025 results on Oct 30, 2024
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹9.61, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 33x in the Biotechs industry in India. Total returns to shareholders of 163% over the past three years.
New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹15m revenue, or US$177k). Market cap is less than US$10m (₹94.2m market cap, or US$1.13m). Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 36x in the Biotechs industry in India. Total returns to shareholders of 155% over the past three years.
お知らせ • Jul 31Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2024, at 10:00 Indian Standard Time. Location: plot no,31, sagar, society, road no.2, banjarahills, hyderabad-500034, hyderabad India
お知らせ • Jul 22Hindustan Bio Sciences Limited to Report Q1, 2025 Results on Jul 31, 2024Hindustan Bio Sciences Limited announced that they will report Q1, 2025 results on Jul 31, 2024
お知らせ • May 12Hindustan Bio Sciences Limited to Report Fiscal Year 2024 Results on May 25, 2024Hindustan Bio Sciences Limited announced that they will report fiscal year 2024 results on May 25, 2024
お知らせ • Jan 12Hindustan Bio Sciences Limited to Report Q3, 2024 Results on Jan 31, 2024Hindustan Bio Sciences Limited announced that they will report Q3, 2024 results on Jan 31, 2024
お知らせ • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2024 Results on Oct 31, 2023Hindustan Bio Sciences Limited announced that they will report Q2, 2024 results on Oct 31, 2023
お知らせ • Sep 05Hindustan Bio Sciences Limited Announces Resignation of Goli Seshavataram, Chief Financial OfficerHindustan Bio Sciences Limited announced that Mr. Goli Seshavataram CFO, of the Company has tendered his resignation from the post of the CFO of the Company with effect from August 30, 2023.
お知らせ • Aug 19Hindustan Bio Sciences Limited Appoints Sukavasi Jyotsna as Company Secretary and Compliance OfficerHindustan Bio Sciences Limited informed that appointment of Mrs. Sukavasi Jyotsna for the post of Company Secretary and Compliance Officer has been approved. Date of Appointment 18th August, 2023. Mrs. Sukavasi Jyotsna is an Associate Member of the Institute of Company Secretaries of India having membership No. ACS 68536. She holds Bachelor Degree in Commerce and having 1 years of experience in the field of Company Secretarial works.
お知らせ • Aug 01Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Agenda: To approve the re-appointment of Mr. Venkata Rama Mohan Raju Jampana.
お知らせ • May 19Hindustan Bio Sciences Limited to Report Q4, 2023 Results on May 30, 2023Hindustan Bio Sciences Limited announced that they will report Q4, 2023 results on May 30, 2023
Board Change • May 11Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Non Executive Independent Director Mantena Raju was the last director to join the board, commencing their role in 2010. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 01Third quarter 2023 earnings released: EPS: ₹0.05 (vs ₹0.002 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.05 (up from ₹0.002 loss in 3Q 2022). Revenue: ₹3.18m (up 33% from 3Q 2022). Net income: ₹476.0k (up ₹496.0k from 3Q 2022). Profit margin: 15% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings.
お知らせ • Jan 23Hindustan Bio Sciences Limited to Report Q3, 2023 Results on Jan 31, 2023Hindustan Bio Sciences Limited announced that they will report Q3, 2023 results on Jan 31, 2023
お知らせ • Jan 13Hindustan Bio Sciences Limited Announces Resignation of Varun Varma Jampana as Non Executive-Non Independent DirectorHindustan Bio Sciences Limited announced that Mr. Varun Varma Jampana, Non Executive-Non Independent Director of the company, vide his letter dated 12 January 2023 has tendered his resignation as Non Executive-Non Independent Director of the company with effect from 12 January 2023.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03Second quarter 2023 earnings released: ₹0.07 loss per share (vs ₹0.05 loss in 2Q 2022)Second quarter 2023 results: ₹0.07 loss per share (further deteriorated from ₹0.05 loss in 2Q 2022). Net loss: ₹749.0k (loss widened 36% from 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 20Hindustan Bio Sciences Limited to Report Q2, 2023 Results on Oct 31, 2022Hindustan Bio Sciences Limited announced that they will report Q2, 2023 results on Oct 31, 2022
お知らせ • Jul 30Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022Hindustan Bio Sciences Limited, Annual General Meeting, Sep 30, 2022.
お知らせ • Jul 19Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 29, 2022Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results at 2:00 PM, Indian Standard Time on Jul 29, 2022
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 6 highly experienced directors. Non-Executive Non-Independent Director Jampana Varma was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 08Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹0.002 loss per share (up from ₹0.11 loss in 3Q 2021). Revenue: ₹2.40m (up ₹2.39m from 3Q 2021). Net loss: ₹20.0k (loss narrowed 98% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 03Second quarter 2022 earnings released: ₹0.05 loss per share (vs ₹0.03 profit in 2Q 2021)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹524.0k (down 84% from 2Q 2021). Net loss: ₹550.0k (down 286% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 09First quarter 2022 earnings released: ₹0.07 loss per share (vs ₹0.05 profit in 1Q 2021)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2022 results: Revenue: ₹1.94m (down 65% from 1Q 2021). Net loss: ₹754.0k (down 250% from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 56% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 01Third quarter 2021 earnings released: ₹0.11 loss per share (vs ₹0.01 profit in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₹2.0k (down 100% from 3Q 2020). Net loss: ₹1.13m (down ₹1.28m from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 76% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Dec 07New 90-day high: ₹3.33The company is up 16% from its price of ₹2.88 on 08 September 2020. The Indian market is also up 16% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 20Market bids up stock over the past weekAfter last week's 17% share price gain to ₹2.17, the stock is trading at a trailing P/E ratio of 13.4x, up from the previous P/E ratio of 11.5x. This compares to an average P/E of 61x in the Biotechs industry in Asia. Total returns to shareholders over the past three years are 309%.
Is New 90 Day High Low • Nov 11New 90-day low: ₹1.73The company is down 6.0% from its price of ₹1.84 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
お知らせ • Jul 18Hindustan Bio Sciences Limited to Report Q1, 2021 Results on Jul 31, 2020Hindustan Bio Sciences Limited announced that they will report Q1, 2021 results on Jul 31, 2020
